Nanobodies as modulators of inflammation: potential applications for acute brain injury
Standard
Nanobodies as modulators of inflammation: potential applications for acute brain injury. / Rissiek, Björn; Nolte, Friedrich; Magnus, Tim.
in: FRONT CELL NEUROSCI, Jahrgang 8, 2014, S. 344.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Nanobodies as modulators of inflammation: potential applications for acute brain injury
AU - Rissiek, Björn
AU - Nolte, Friedrich
AU - Magnus, Tim
N1 - Frontiers in cellular neuroscience-Kurztitel nicht auswählbar :-(
PY - 2014
Y1 - 2014
N2 - Nanobodies are single domain antibodies derived from llama heavy-chain only antibodies (HCAbs). They represent a new generation of biologicals with unique properties: nanobodies show excellent tissue distribution, high temperature and pH stability, are easy to produce recombinantly and can readily be converted into different formats such as Fc-fusion proteins or hetero-dimers. Moreover, nanobodies have the unique ability to bind molecular clefts, such as the active site of enzymes, thereby interfering with the function of the target protein. Over the last decade, numerous nanobodies have been developed against proteins involved in inflammation with the aim to modulate their immune functions. Here, we give an overview about recently developed nanobodies that target immunological pathways linked to neuroinflammation. Furthermore, we highlight strategies to modify nanobodies so that they can overcome the blood brain barrier and serve as highly specific therapeutics for acute inflammatory brain injury.
AB - Nanobodies are single domain antibodies derived from llama heavy-chain only antibodies (HCAbs). They represent a new generation of biologicals with unique properties: nanobodies show excellent tissue distribution, high temperature and pH stability, are easy to produce recombinantly and can readily be converted into different formats such as Fc-fusion proteins or hetero-dimers. Moreover, nanobodies have the unique ability to bind molecular clefts, such as the active site of enzymes, thereby interfering with the function of the target protein. Over the last decade, numerous nanobodies have been developed against proteins involved in inflammation with the aim to modulate their immune functions. Here, we give an overview about recently developed nanobodies that target immunological pathways linked to neuroinflammation. Furthermore, we highlight strategies to modify nanobodies so that they can overcome the blood brain barrier and serve as highly specific therapeutics for acute inflammatory brain injury.
U2 - 10.3389/fncel.2014.00344
DO - 10.3389/fncel.2014.00344
M3 - SCORING: Journal article
C2 - 25374510
VL - 8
SP - 344
JO - FRONT CELL NEUROSCI
JF - FRONT CELL NEUROSCI
SN - 1662-5102
ER -
